http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt
-
Westbridge Renewable Energy to Present at the Planet MicroCap Showcase in Toronto
-
Surge Battery Metals Advances 2025 Drill Program; Leverages U.S. Critical Minerals Policy
-
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
-
BD launches AI-enabled platform for healthcare device connectivity
-
Imperfect but Unstoppable: Italian Wine Podcast Smashes 2500 Episodes to Become the World's Most Prolific Wine Podcast
-
BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings
-
Merck begins construction of $3 billion manufacturing facility in Virginia
-
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
-
CoinEx Reinforces Transparency with Updated Proof of Reserve – October 2025
-
CoinLander Launches RWA Platform, Unlocking Stable Returns from Tokenized Real Estate Mortgages
-
Exelixis reports survival benefit for zanzalintinib combo in colorectal cancer
-
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO
-
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
-
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Daiichi Sankyo and Merck's ovarian cancer drug shows 50.5% response rate
-
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
-
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
-
Crypto News (Live): From $0.0075 to $0.50? Blazpay’s AI Presale Heats Up as Solana and BNB Investors Seek New Gains
-
Darkness to Light Expands National Scholarship Program Empowering Child Protection Leaders
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
-
Medome Launches New Medical Industry: Personal Health Intelligence TM - AI-Powered Personal Health Records to Usher In New Era of DIY Healthcare for ALL Americans
-
Masters Of Ring Entertainment Revolutionizes Professional Wrestling Industry with Triple Platform Launch
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Ba
-
EXEL reports CABOMETYX reduced disease progression risk by 81% in lung tumors
-
Blazpay’s Phase 2 of Crypto Presale Surges With Over $250,000 Raised as XRP and Bitcoin Consolidate
-
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
-
Zoomex Announces Argentine Football Star Emiliano Martínez as Its Global Exclusive Brand Ambassador
-
Canadian Securities Exchange Reports September 2025 Performance Figures
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHARE
-
VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHARE
-
New Break Increases Moray Property Position Through Acquisition and Staking
-
Ethema Files Q1 2025 Quarterly Results
-
Parent Project Muscular Dystrophy Celebrates 20th Annual Sam's Night Event, Marks Two Decades of Community Impact, Growth, and Hope for Families Living with Duchenne
-
Crypto Alert: Blazpay Phase 2 Presale Live at $0.0075 Amid XRP and ETH Market Strength
-
BROAD ARROW’S WYNN LAS VEGAS AUCTION FEATURES SOUGHT-AFTER CARS FOR EVERY COLLECTOR’S TASTE
-
Citi Appointed as Depositary Bank for POMDOCTOR LIMITED’s ADR Program
-
Blazpay’s Crypto Presale Phase 1 Ends in Next 24 Hours as XRP and Solana Face Market Turbulence
-
RAMSAY SANTE : annual results at the end of June 2025
-
UpWeGo Officially Launches its New Driven Meme Coin with the Slogan The Only Way is Up for this Community
-
AmeraMex Secures $622,000 in Equipment Orders
-
CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2025
-
Becky G and Garnier Celebrate Hispanic Heritage Month with Free Block Party in Downtown Los Angeles
-
Montefiore Einstein and Dandelion Partner to Accelerate AI-Driven Drug Development and New Clinical Care Solutions
-
AbbVie completes acquisition of Gilgamesh's depression drug bretisilocin
